Literature DB >> 25703908

A comparison of the effects of morphine and sublingual desmopressin combination therapy with morphine alone in treatment of renal colic: a controlled clinical trial.

Maliheh Keshvari Shirvani1, Mohammadreza Darabi Mahboub, Mahdi Ghazi, Alireza Delijani.   

Abstract

PURPOSE: To compare the therapeutic efficacy of combined desmopressin and morphine with morphine and placebo on acute renal colic.
MATERIALS AND METHODS: In a single blind case-control clinical trial 81 consecutive patients, 54 males and 27 females with the mean age of 30.12 ± 9.88 years, presenting with acute renal colic to the urology emergency unit were studied. The patients were randomly assigned into two groups. The 40 cases were treated with 0.1 mg/kg IM morphine and 60 μg of sublingual desmopressin melt; whereas the 41 controls received the same dose of morphine beside a placebo.
RESULTS: There were no significant statistical differences regarding the mean age, gender, stone size, location and affected side between the two groups. Our results showed a significantly higher acuity of pain in the study group in comparison to the controls at 10, 20 and 30 minutes of receiving the medication (P = .06, .017 and P = .008, respectively).
CONCLUSION: No superiority was found in adding desmopressin to morphine compared to the traditional treatments (opioids only) in relieving the pain of acute renal colic cases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25703908

Source DB:  PubMed          Journal:  Urol J        ISSN: 1735-1308            Impact factor:   1.510


  2 in total

1.  Analgesic Effects and Safety of Desmopressin, Tramadol and Indomethacin in Patients with Acute Renal Colic; A Randomized Clinical Trial.

Authors:  Mehdi Shirazi; Mehdi Salehipour; Mohammad Amin Afrasiabi; Alireza Aminsharifi
Journal:  Bull Emerg Trauma       Date:  2015-04

2.  Sublingual desmopressin is efficient and safe in the therapy of lithiasic renal colic.

Authors:  Catalin Pricop; Dumitru D Branisteanu; Martha Orsolya; Dragos Puia; Anca Matei; Ionel Alexandru Checherita
Journal:  Int Urol Nephrol       Date:  2015-12-16       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.